Latest news with #oligodendroglioma
BBC News
4 days ago
- General
- BBC News
Worcestershire brain cancer patient, Ben Lindon, has died
A brain cancer patient who fought to raise awareness of the disease and help others has Ben Lindon, 46, from Malvern, passed away last Thursday, 16 years after he was diagnosed with an aggressive and rare brain tumour called an oligodendroglioma, the charity Brain Tumour Research his diagnosis, he started running and training, and completed the Brighton Marathon, among others, in wife, Kate, said: "Instead of allowing the diagnosis to define or defeat him, Ben chose to lead a healthier life physically and mentally, and to focus on others who were also suffering." The former journalist and retained firefighter for Warwickshire Fire and Rescue Service also completed the Three Peaks Challenge, the London Marathon, and a 1,000-mile bike ride from John O'Groats to Land's Jones, the charity's head of fundraising, described him as "an extraordinary individual whose courage, determination and tireless fundraising inspired everyone who knew him".The charity described how the risks were too high to remove Mr Lindon's tumour surgically, and he underwent 120 cycles of radiotherapy and chemotherapy, thought to be the most chemotherapy given to any patient in the his 100th chemo cycle in 2017, he kayaked 100 miles along the River Wye, supported by mementos from his Lindon, who is working with the organisation to raise awareness of the disease, has described how he raised more than £10,000 for Brain Tumour Research, as he "fought a brave battle, raising awareness and support".She said: "Ben wanted others to have a fighting chance, and he knew that fundraising was his way of trying to ensure that other families don't have to experience what he went through." Follow BBC Hereford & Worcester on BBC Sounds, Facebook, X and Instagram.
Medscape
6 days ago
- Health
- Medscape
Brain Tumors Clinical Practice Guidelines (2025)
Editorial Note: These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference. Updated guidelines on therapy of adult diffuse astrocytic and oligodendroglial tumors were published in April 2025 by the American Society of Clinical Oncology and the Society for Neuro-Oncology in the Journal of Clinical Oncology .[1] In patients with oligodendroglioma that is IDH -mutant, 1p19q co-deleted, central nervous system (CNS) World Health Organization (WHO) grade 2, offer radiation in combination with procarbazine, lomustine (CCNU), and vincristine (PCV). If toxicity is a concern, temozolomide is a reasonable alternative to PCV. Consider offering vorasidenib to patients who have oligodendroglioma that is IDH -mutant, 1p19q codeleted, CNS WHO grade 2; who have undergone one or more surgeries; and in whom further treatment with radiation and chemotherapy has been or can be deferred. In astrocytoma that is IDH -mutant, 1p19q non-codeleted, CNS WHO grade 2, initial radiation therapy and chemotherapy (with temozolomide or PCV) may be deferred until radiographic or symptomatic progression in some patients with favorable prognostic factors (eg, complete resection, younger age) or concerns about short- and long-term toxicity. Consider offering vorasidenib in patients who have astrocytoma that is IDH -mutant, 1p19q non-codeleted, CNS WHO grade 2; who have undergone one or more surgeries; and in whom further treatment with radiation and chemotherapy has been or can be deferred. For more information, please go to Brain Neoplasms.
